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Background:  The mitogen-activated protein (MAP) kinases are important
signaling molecules that participate in diverse cellular events and are potential
targets for intervention in inflammation, cancer, and other diseases. The MAP
kinase p38 is responsive to environmental stresses and is involved in the
production of cytokines during inflammation. In contrast, the activation of the
MAP kinase ERK2 (extracellular-signal-regulated kinase 2) leads to cellular
differentiation or proliferation. The anti-inflammatory agent pyridinylimidazole and
its analogs (SB [SmithKline Beecham] compounds) are highly potent and
selective inhibitors of p38, but not of the closely-related ERK2, or other
serine/threonine kinases. Although these compounds are known to bind to the
ATP-binding site, the origin of the inhibitory specificity toward p38 is not clear.
Results:  We report the structural basis for the exceptional selectivity of these
SB compounds for p38 over ERK2, as determined by comparative
crystallography. In addition, structural data on the origin of olomoucine (a better
inhibitor of ERK2) selectivity are presented. The crystal structures of four SB
compounds in complex with p38 and of one SB compound and olomoucine in
complex with ERK2 are presented here. The SB inhibitors bind in an extended
pocket in the active site and are complementary to the open domain structure of
the low-activity form of p38. The relatively closed domain structure of ERK2 is
able to accommodate the smaller olomoucine.
Conclusions:  The unique kinase–inhibitor interactions observed in these
complexes originate from amino-acid replacements in the active site and
replacements distant from the active site that affect the size of the domain
interface. This structural information should facilitate the design of better
MAP-kinase inhibitors for the treatment of inflammation and other diseases.
Introduction
The ubiquitous mitogen-activated protein (MAP) kinases
are important components in signal-transduction cascades
that regulate diverse cellular events such as cell transfor-
mation, proliferation, differentiation, and apoptosis [1–6].
They are therefore potential drug targets for therapeutic
intervention in the treatment of inflammation, cancer,
leukemia, and other diseases [7–9]. Over a dozen MAP
kinases have been cloned and the best characterized of
these are the extracellular-signal-regulated kinases (ERKs)
[10,11], the c-Jun N-terminal kinases (JNKs) [12–14] and
p38 (or CSBP2) [7,15–17]. Each MAP kinase is activated
by dual phosphorylation of a conserved threonine and
tyrosine residue in the activation loop. However, each
kinase activates a unique spectrum of cellular targets, and,
together with their upstream activators, defines indepen-
dent signaling pathways, which are responsive to differ-
ent extracellular stimuli. Whereas ERK2 is activated in
response to hormones and growth factors [10,11,18], JNKs
and p38 are activated by lipopolysaccharide (LPS) and
by environmental stresses such as heat shock, hyper-
osmolarity, and radiation [19–21]. The recent discovery
that specific inhibitors of p38 block the production of
proinflammatory cytokines has generated significant inter-
est in the MAP kinases as drug targets [7].
The CSAIDTM (cytokine suppressive anti-inflammatory
drugs) class of anti-inflammatory compounds inhibits the
LPS-induced synthesis of cytokines, such as interleukin-1
(IL-1) and tumor necrosis factor (TNF), in human mono-
cytes by specific inhibition of the MAP kinase p38
[3,7,22]. These SB (SmithKline Beecham) compounds,
typified by the pyridinylimidazole SB203580 and the
pyrimidinylimidazole SB220025, have IC50 values of
10–100 nM as p38 inhibitors [3,23], and are pharmacologi-
cally active in animal models for inflammatory diseases
such as arthritis and bone resorption [24].
The SB compounds inhibit p38 — both the activity of the
phosphorylated enzyme and its autophosphorylation is
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affected [25]. SB compounds have been shown to be com-
petitors of ATP [25], and to bind to the ATP site [26,27]
with a 1:1 molar stoichiometry. These compounds are
highly selective for p38 and exhibit no, or very weak,
inhibitory activity toward the closely related MAP kinases
JNKs and ERKs [3], despite the fact that the inhibitors
bind to the ATP site. The discovery of the class of highly
specific protein-kinase inhibitors suggests that protein
kinases generally may be targeted selectively for thera-
peutic intervention. It therefore becomes important to
understand the origin of the specificity of the ATP-site-
directed compounds. We have used X-ray crystallography
to study the interactions of four SB compounds with the
unphosphorylated form of p38. We also studied the inter-
action of ERK2 with one SB compound that weakly
inhibits it. Finally, we determined the structure of olo-
moucine, which is a weak inhibitor of ERK2 but shows
almost no inhibitory activity toward p38, bound to ERK2.
By means of these comparative studies, we have defined
the origin of specificity and potency of these ATP-site-
directed protein-kinase inhibitors.
The structures of the unphosphorylated forms of both
ERK2 [28] and p38 [29,30], as well as the phosphorylated
and activated form of ERK2 [31], have been determined.
The unphosphorylated forms of p38 and ERK2 are topolog-
ically similar, but the activation loop (lip) is shorter in p38
than in ERK2 and it adopts a distinct position that is closer
to the active site than it is in the ERK2 structure. The
domain separation is greater in p38 and the domain inter-
face is shaped differently to that of ERK2 (Figure 1). These
differences, as well as specific amino-acid replacements,
affect the geometry of the ATP-binding site [29]. Phospho-
rylated ERK2 has a more closed domain structure than its
low-activity form and it assumes a different conformation in
the phosphorylation lip and adjacent structures [31]. The
active forms of ERK2 and p38 might be more similar than
the low-activity forms because they catalyze the same reac-
tion and have the same activation mechanism [29,32].
Direct binding assays have shown that binding of the SB
inhibitors to the low-activity form of p38 is correlated with
inhibitory activity [25]. Inhibitor binding to both unphos-
phorylated and phosphorylated forms has been shown to
be competitive with ATP [25]. The present studies focus
on complexes of inhibitors bound to the low-activity forms
of p38 and ERK2. Four SB compounds were studied in
complex with p38, and one in complex with ERK2. Fur-
thermore, the structure of olomoucine, which is a weak
inhibitor of ERK2 but not of p38, was determined in
complex with ERK2.
Results
The four SB compounds, SB1(SB203580)[4-(4-fluoro-
phenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imida-
zole], SB2(SB216995), SB3(SB218655), and SB4(SB220025)
[5-(2-amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piper-
idinyl)imidazole], contain a core imidazole ring, a pyridine
or pyrimidine ring bonded to the imidazole C5 atom, a
4-fluorophenyl ring bonded to C4, and another functional
group at either C2 or N1 (Figure 2). These chemical struc-
tures are slightly different, resulting in IC50s that vary from
20 to 150 nM (Figure 2). The inhibition constants for
SB1–4 were also measured for ERK2 and were found to
range from 20 µM to greater than 1 mM. A second group of
compounds studied were commercially available protein-
kinase inhibitors, including olomoucine [33]. Olomoucine,
a specific cyclin-dependent-kinase inhibitor, weakly inhibits
ERK2, with an IC50 of ~ 27 µM, but does not inhibit 
p38 (Figure 2).
Crystals of p38 and ERK2 were bathed in solutions contain-
ing either the SB compounds or olomoucine. All four SB
compounds were successfully introduced into crystals of
p38 (Table 1). Of the four SB compounds tested, only one,
SB4, bound to crystals of low-activity ERK2. Olomoucine
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Figure 1
Superposition of unphosphorylated p38 (green and blue) and ERK2
(purple and red) using corresponding Cα atoms in the C-terminal
domain (residues 110–320 in p38). The molecules differ greatly in
domain orientation and in the conformation of the activation loop. The
N-terminal domain of p38 is rotated 16° in comparison to that of ERK2.
The figure was produced using the program SETOR [58].
was soaked into crystals of both p38 and ERK2, but it
bound only to crystals of ERK2. All structures were solved
using data at 2.5 Å resolution or better. X-ray data-collection
and refinement statistics are given in Table 1. Each of the
structures has been refined to an R factor of 21% or better
on available data. Several other protein-kinase inhibitors
were soaked into the p38 and ERK2 crystals, but did not
bind even with elevated inhibitor concentrations and
prolonged soaking time. These included genestein [34],
quercetin [35], and PD98059 [36].
Inhibitors bind in the ATP site
The structural data show that each of the compounds
studied binds to p38 or ERK2 between the two domains
of the kinase, in the ATP-binding site (Figures 3 and 4).
One ring of each compound occupies a position similar to
that of the adenine ring of ATP (Figure 3). Furthermore, a
hydrogen bond between a conserved hydrophobic residue
in the crossover connection of protein kinases and the
adenine N1 atom of ATP, which is conserved in known
protein kinase–ATP complexes [28,37,38], is recapitulated
in the kinase–inhibitor interactions. The nitrogen atom in
the pyridine/pyrimidine ring of the SB compounds accepts
a hydrogen bond from the backbone amide of Met109 of
p38. A similar hydrogen bond is formed in ERK2–olo-
moucine, as well as in other protein kinase–inhibitor com-
plexes [39–42]. It therefore appears that this interaction is
essential for binding.
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Figure 2
Chemical structure and protein kinase activity
of inhibitors used in the study.
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Structure
Structure of p38–SB1 complex 
Compound SB1(SB203580; Figure 2) has three rings
attached to a central imidazole, which form a propeller.
The pyridine ring of SB1 partially overlaps the adenine
ring of ATP in the p38–SB1 complex. Like ATP, the
pyridine ring N atom accepts a hydrogen bond (2.8 Å)
from Met109N in the crossover connection. The inter-
actions made by SB1 are, however, otherwise distinct
from ATP (Figures 4a and 5a). SB1 binds mainly to the
N-terminal domain; the N3 atom which is apparently not
protonated, of the imidazole ring of SB1 binds to Lys53Nε
(2.9 Å). The fluorophenyl ring binds in a hydrophobic
pocket with walls formed by the N-terminal domain core
β sheet and helix C at the back of the active site
(Figure 5a). One edge of the fluorophenyl ring makes van
der Waals contacts with the backbone of β strands 3 and 5,
interdigitated between the sidechains of Thr106 and
Leu104; the opposite edge forms van der Waals contacts
with Leu75 in helix C and Leu86 in strand β4. The fluorine
atom forms a short contact (3.3 Å) with Val105N, although
the geometry is not suggestive of hydrogen bonding [43].
The 4-methylsulfinylphenyl group contacts the phosphate-
binding ribbon, and the phenyl ring forms a stacking inter-
action with Tyr35. The methylsulfinyl moiety (racemic
mixture), visible in the electron density is near the activa-
tion loop, but makes no direct contacts with the protein.
SB1 induces local conformational changes in p38; Thr106
adopts a different rotamer in the SB1 complex and forms a
van der Waals contact with the fluorophenyl moiety of SB1.
In the new position, Thr106 particpates in an extended
network of water-mediated hydrogen bonds involving
His107 (Figure 6). Also, the phosphate-binding ribbon has
improved electron density in the complex and changes con-
formation slightly (Figure 7), bringing Tyr35 into contact
with the methylsulfinylphenyl ring. The inhibitor binding
induces an ion pair, not present in the uncomplexed low-
activity form of p38, between Lys53Nε and Glu71Oδ.
Structures of p38–SB2 and p38–SB3 complexes
The imidazole N1 atom in SB2 is substituted with a cyclo-
propylmethyl group (Figure 2). The Met109N–pyridine
hydrogen bond (3.0 Å) is formed in p38–SB2. As with SB1,
all of the remaining interactions are with the N-terminal
domain (Figures 4a and 5b); the cyclopropylmethyl group
binds to the phosphate-binding ribbon in a depression
formed by Val30 and Val38. The interaction between the
imidazole N3 and Lys53Nε is more distant (3.7 Å) than in
p38–SB1, as is the contact between Val105N and the
flourine atom of the inhibitor (3.5 Å). Furthermore, there is
no stacking interaction between Tyr35 and the inhibitor.
The conformation of the phosphate-binding ribbon changes
significantly to form the interaction with SB2 (Figure 7).
SB3 is quite similar to SB2, but the pyridine ring of SB2
is replaced by a 2-aminopyrimidine ring in SB3 (Figure 2).
This small change greatly improves the binding strength
(Figure 2) and causes a difference in the binding mode
(Figure 7). Both the M109N–pyrimidine N (2.9 Å) and
the Lys53Nε–imidazole N3 (2.9 Å) hydrogen bonds are
formed in p38–SB3, as is the contact between Val105N
and the fluorine atom (3.4 Å). In addition, the amino group
of the pyrimidine ring makes an additional weak hydro-
gen bond with Met109O (3.3 Å, Figure 5c). The cyclo-
propyl ring makes closer hydrophobic interactions with
Val30 and Val38 and it also forms contacts with Tyr35. As
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Table 1
Data collection and refinement statistics.
Complex p38–SB1 p38–SB2 p38–SB3 p38–SB4 ERK2–SB4 ERK2–olomoucine
X-ray diffraction data
Space group P212121 P212121 P212121 P212121 P21 P21
Resolution limit (Å) 2.4 2.5 2.4 2.5 2.1 2.1
No. of observations 227 945 344 423 200 387 237 558 75 337 99 305
Unique reflections 19 984 18 307 19 500 17 921 26 102 26 042
Completeness (%) 92.4 99.1 99.4 84.3 90.0 85.0
Rsym* (%) 4.2 5.4 5.0 5.0 4.0 4.2
Refinement
Resolution (Å) 20–2.5 20–2.5 20–2.4 20–2.5 20–2.1 20–2.2
No. of reflections (F > 2σ) 17 771 18 098 19 326 14 726 22 843 21 742
Rcryst/Rfree† (%) 18.2/24.0 18.9/24.6 18.9/24.9 18.9/24.5 20.3/26.4 20.8/32.7
No. of waters 90 71 94 56 136 124
*Rsym = ΣhklΣiIi(hkl) – I(hkl)/ ΣhklΣi Ii(hkl) where Ii(hkl) is the intensity of an individual measurement, and I(hkl) is the mean intensity of this
reflection. †R factor = Σ Fobs–Fcal/ ΣFobs, where Fobs and Fcal are the observed and calculated structure factors, respectively; ten percent
of the complete data set was excluded from refinement to calculate Rfree.
with SB2, conformational changes and improved order
are observed in the phosphate-binding ribbon in the
p38–SB3 complex (Figure 5c).
Structure of p38–SB4 complex
In SB4, a piperidine ring replaces the cyclopropyl ring of
SB2 and SB3 as the third blade of the propeller and
occupies the space between the two domains of p38
(Figures 4a and 5d). The ring forms an edge-to-face inter-
action with Tyr35 in the phosphate-binding ribbon, and
the nitrogen N4 forms a hydrogen bond with Asp168Oδ1
(Figure 5d) in the C-terminal domain. Conformational
changes occur in the phosphate-binding ribbon that bring
Tyr35 into a position where it can interact with the piperi-
dine ring (Figure 5d). The stereochemistry of the interac-
tions of SB4 differ slightly from those of SB3; the
interactions of the fluorophenyl ring appear to be more
intimate — the distance between Val105N and the fluo-
rine atom of SB4 is 2.9 Å. On the other hand, the hydro-
gen bond from the amino group in the 2-aminopyrimidine
ring to Met109O in SB3 is weaker in SB4 (3.8 Å). The net
effect of these altered interactions is that SB3 and SB4
have similar potency as p38 inhibitors.
Structure of ERK2–SB4 complex
Although SB4 is not a potent inhibitor of ERK2, it does
bind to crystals of low-activity ERK2 at a soaking con-
centration of 1 mM. In the ERK2–SB4 complex (Figures 3b,
4b and 8a), the origin of the weaker binding affinity is
apparent. Firstly, the Met106N–pyrimidine N distance is
longer (3.2 Å), secondly, the interactions of the 4-fluo-
rophenyl ring are more distant and the fluorine atom is
3.9 Å away from Val102N, and thirdly, the imidazole N3
does not contact Lys52Ne (4.0 Å). Also, the piperidine
ring makes no stacking interaction with Tyr34 (Tyr35 in
p38), but it forms hydrogen bonds with Asp109Oδ (Asp112
in p38) of the C-terminal domain. The 2-aminopyrimi-
dine ring is rotated 180° relative to its orientation in p38–
SB4 (Figure 3) and it forms a hydrogen bond, not present
in p38–SB4, with Asp104O (Figure 8a). SB4 also induces
fewer conformational changes in ERK2 than in p38 (not
shown); whereas Thr106 rotates in p38, no corresponding
conformational change occurs in Gln103 of ERK2. The
inhibitor does not form a tight interaction with Tyr34 in
the phosphate-binding ribbon and the conformation of
this loop changes very little. Tyr34 makes an aromatic
stacking contact, with Tyr62 in helix C (His64 in p38;
Figure 9), that may prevent the necessary conformational
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Figure 3
Electron-density maps showing SB4 bound to both p38 and ERK2,
and ATP bound to ERK2. Difference electron-density maps were
calculated using phases derived from models of (a) p38 or (b) ERK2,
with inhibitor omitted, using the program REFMAC [54], contoured at
2σ. (c) The binding mode for ATP with ERK2 is shown for comparison.
changes in the phosphate-binding ribbon that occur in the
p38–SB complexes in response to the inhibitor binding.
Tyr34 does change position in ATP-bound ERK2, however
(Figure 3c [28]).
The cause of the weaker binding of SB4 to ERK2 is
apparent from the structure. Firstly, the size of the pocket
in which the fluorophenyl ring binds is smaller in ERK2.
This is mainly a result of Thr106 in p38 being replaced
with Gln103 in ERK2. Secondly, the hydrophobic pocket
for binding the fluorophenyl ring is not formed because
helix C occupies a different position. As a consequence,
Leu73 (Leu75 in p38), which contacts the fluorophenyl
ring in p38, is shifted by 3 Å in ERK2.
Structure of ERK2–olomoucine complex
Olomoucine binds to ERK2, but not to p38. It adopts a
different binding mode from that of SB4 (Figure 4b). The
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Figure 4
2|Fo|–|Fc| electron density maps of 
(a) p38–SB1–4 and (b) ERK2—SB4 and
ERK2—olomoucine complexes, around the
inhibitor and contoured at 1σ. The maps were
calculated in the program X-PLOR [56] using
sigmaA-weighted coefficients and model-
derived phases for diffraction data between
20 and 2.5 Å. The maps were drawn using the
programs BOBSCRIPT [59] and POV-Ray
version 3.01.
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Figure 5
Stereo diagram showing interactions of p38
with inhibitors (a) SB1, (b) SB2, (c) SB3, and
(d) SB4. Hydrogen bonds between the
inhibitors and the protein molecule, as well as
a short contact between Val105N and the
fluorine atom (magenta) of the fluorophenyl
ring, are shown as red dashed lines.
purine ring of olomoucine occupies the same site as the
adenine ring of ATP, and it is interdigitated between
Ile29, Val37, Ala50, and Leu154. Two hydrogen bonds are
formed between olomoucine and the backbone of ERK2:
the conserved hydrogen bond from Met106N to purine
N7 (2.7 Å), and an additional bond from the benzylamino
N to Met106O (2.5 Å; Figure 8b). Olomoucine induces a
~1° domain closure and conformational changes in the
phosphate-binding ribbon in ERK2. The benzene ring of
the benzylamino group displaces Lys112 in helix D, and
contacts Lys112 and the backbone of Thr108. Like SB4,
olomoucine forms no contact with Lys52Nε. The OH of
the hydroxyethylamino moiety orients toward Asp119 and
Lys112, but forms no contacts with these residues.
Discussion
So far, all low molecular weight protein-kinase inhibitors
studied crystallographically bind to the enzymes’ ATP-
binding sites [39–41,44,45]. Nevertheless, a surprising level
of specificity has been observed for some protein-kinase
inhibitors. With the six MAP kinase–inhibitor complex
structures determined here, we have the opportunity to
define the origin of the specificity and the potency of the
SB inhibitors toward p38, and to understand structural dif-
ferences in the MAP kinases that give rise to a surprising
level of inhibitor selectivity.
In the three-blade propeller structure of the SB com-
pounds, one blade, which is a pyridine or pyrimidine ring,
makes a hydrogen bond that is conserved in complexes
with ATP and with other protein kinase inhibitors. The
other two blades of the three-blade propeller structure, as
well as the imidazole ring, are involved in specificity deter-
mination. The fluorophenyl ring binds in a pocket unique
to p38, between the sidechains of residues in the N-termi-
nal domain β sheet and helix C. Although SB4 binds
ERK2, the binding pocket for the fluorophenyl ring is
clearly smaller and malformed, perhaps accounting for the
200-fold lower potency of SB4 for ERK2. The third blade
of the propeller of the SB compounds is also involved in
inhibitor selectivity. In SB1, the methylsulfinylphenyl ring
at position C2 is tightly associated with the phosphate-
binding ribbon and forms a stacking interaction with
Tyr35. SB1 does not bind to ERK2, in part because the
methylsulfinylphenyl-binding site is narrower in ERK2,
and because Tyr34 is preferentially engaged with Tyr62
in helix C. SB2, SB3, and SB4 are substituted at the N1
position. The cyclopropylmethyl ring in SB3 forms a close
1124 Structure 1998, Vol 6 No 9
Figure 6
Thr106 of p38 plays a crucial role in the
p38–SB inhibitor interactions. (a) In the
native p38 structure, Thr106 forms an
interaction with a water molecule. (b) In the
p38–inhibitor complex, Thr106 rotates
around χ1 for about 120° and participates in
the nearby hydrogen-bonding network that
also involves His107. β strands in the N-
terminal domain are colored green.
Figure 7
Superposition of native p38 and four p38–SB inhibitor complexes
around the inhibitors and the phosphate-binding ribbon.
Superposition was calculated in the program O [55] using the Cα
atoms from residue 20 to 320 in p38. Unliganded p38 is in gray,
p38–SB1 is in purple, p38–SB2 is in green, p38–SB3 is in orange
and p38–SB4 is in blue.
hydrophobic interaction with Val30, Val38 and Tyr35 in
the phosphate-binding ribbon. This interaction is appar-
ently important for the better affinity of SB3. ERK2 does
not bind to SB2 or SB3, despite the fact that it has the
residues Ile29 and Val37 that form the cyclopropyl-
binding pocket. This lack of binding may be due, in part,
to a difference in flexibility of the phosphate-binding
ribbon (discussed below). In p38–SB4, the piperidinyl ring
binds to Asp168Oδ1 in the C-terminal domain and forms a
different stacking interaction with Tyr35. ERK2 does
bind SB4 and the interaction of the piperidinyl moiety of
SB4 with Asp109Oδ and Lys112Nε of ERK2 may con-
tribute to the strength of the interaction.
Specific amino-acid replacements in the active site are
important for the differential binding of inhibitors. The
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Figure 8
Stereo diagram showing interactions of ERK2
with inhibitors (a) SB4 and (b) olomoucine.
Hydrogen bonds between the inhibitors and
the protein molecule, as well as the contact
between Val102N and the fluorine atom
(magenta), are shown as red dashed lines. 
Figure 9
Comparison of the structures of p38–SB4
and ERK2–SB4 in the region of the inhibitor-
binding site. (a) Tyr35 in the p38–SB4
complex is oriented towards the inhibitor-
binding site, makes an important interaction
with the inhibitor and has no contact with helix
C. (b) In the ERK2–SB4 complex, the
corresponding interaction between Tyr34 and
the inhibitor is lost; instead Tyr34 makes a
stacking interaction with Tyr62 (His64 in p38)
located on helix C.
interaction of the fluorophenyl ring with p38 relies on the
fact that Thr106 in p38 is small enough to accommodate
it. The fluorophenyl ring rotates to form the interaction
and changes a network of water-mediated hydrogen bonds
that involve both Thr106 and His107. Introduction of
His107, in addition to Thr106, into the highly similar MAP
kinases SAPK3 and SAPK4 [46–48] increases the sensitiv-
ity to SB1 (Gum et al., [49]), indicating that the hydrogen-
bonding network contributes to the apparent inhibitor
affinity. Like SAPK3 and SAPK4, ERK2 lacks Thr106 and
His107. Gln103 in ERK2 (Thr106 in p38) reduces the size
of the binding pocket occupied by the fluorophenyl ring.
Other amino-acid replacements influence inhibitor binding
as well — Ile29 and Leu154 in ERK2 (Val30 and Ala157
in p38) are important for forming the relatively small
binding pocket for olomoucine. In addition, Asp109 and
Lys112 in ERK2 (Asn115 in p38) are involved in binding
both olomoucine and SB4.
Differences in the overall domain structures of p38 and
ERK2 may contribute to inhibitor specificity. The inter-
action of the fluorophenyl ring depends on the relative
position of helix C and the N-terminal domain β sheet.
Residues Leu75 and Leu86 are aligned to enable contact
with the fluorophenyl ring in p38, but not in ERK2. In
ERK2, helix C occupies a different position and Leu73 is
shifted 3 Å relative to its position in p38. The wider domain
separation also appears to permit the binding of SB1 into
p38, but not into ERK2. In contrast, small inhibitors such
as olomoucine bind to ERK2 but not to p38. The benzyl
group of olomoucine contacts Ile29 in β1, in a similar
manner to the interaction found in CDK2–olomoucine
[39]. In p38, however, modeling suggests that this inter-
action could not be formed simultaneously with the con-
served hydrogen bonds to the crossover connection, because
of the wider domain separation in p38. The origin of the
differences in domain structure has been discussed previ-
ously [29] and involves mainly the interaction of helix C
and the activation loop.
Differences in flexibility of the phosphate-binding ribbon
[50] may play a role in inhibitor selectivity. In each of the
p38–SB complexes, the phosphate-binding ribbon changes
shape, bringing Tyr35, which is disordered in unliganded
p38, into contact with the inhibitor (Figure 6). No similar
conformational changes are observed in ERK2. In ERK2,
the corresponding Tyr34 forms a tight stacking interaction
with Tyr62 in helix C that locks the conformation of the
phosphate-binding ribbon. In addition, Tyr28 and Arg13
in ERK2 form a stacking interaction that anchors the
phosphate-binding ribbon. Thus, residues distal to the
active site, Arg13, Tyr28, and Tyr62 (in ERK2) may influ-
ence inhibitor binding.
It is interesting that the p38 inhibitors bind to, and appear
to be complementary to, the low-activity structures studied
here. The SB compounds are shown to inhibit the weak
activity of the unphosphorylated form of p38 [25], and
thus may bind to the open, low-activity form of the kinase
preferentially. The ATP-binding sites of the activated
enzymes may be more similar to each other than the sites
in the low-activity forms as a result of the requirements of
the stereochemistry of the phosphotransfer reaction, and
the conservation of the phosphorylation sites and the amino
acids that ligand covalently bound phosphates [32,51]. It is
possible that the inhibitors mold the active site to adopt
the low-activity structure in the region of the active site as
part of the inhibition process. A mechanism involving
preferential binding to the low-activity conformation of
these proteins may help to explain the selectivity achieved
with this class of protein-kinase inhibitors.
Biological implications
Selective protein-kinase inhibitors should be an impor-
tant basis for the development of anti-inflammatory,
anticancer, and other therapeutics. Pyridineimidazole
compounds (SB compounds) have been shown to be
highly selective for the mitogen-activated protein (MAP)
kinase p38, but not effective on the closely related MAP
kinase ERK2 (extracellular-signal-regulated kinase 2). In
contrast, olomoucine, a cdk2 (cyclin-dependent kinase 2)
inhibitor, is weakly effective against ERK2, but not p38.
The comparative crystallographic analysis presented here
elucidates the molecular basis for these inhibitor selec-
tivities. The ATP-binding sites, to which the inhibitors
bind, are quite different in the two MAP kinases. The
differences arise from altered domain structures as
well as specific amino-acid replacements in the active
site. In addition, altered flexibility of the phosphate-
binding ribbon affects the ability of the two proteins to
bind inhibitors. Both the differences in domain struc-
ture and the differences in flexibility arise from amino-
acid replacements well outside the active site. These
changes probably contribute significantly to the sur-
prising fact that it is possible to make specific inhibitors
of individual protein kinases. The results of this com-
parative study can be used to improve the selectivity of
p38 inhibitors and to find new potent inhibitors for
ERK2 and c-Jun N-terminal kinases (JNKs).
Materials and methods
Human p38 was encoded in and expressed from a vector comparable
to that used previously [29]. Expression, purification and crystallization
of low-activity p38 and ERK2 were carried out as described previously
[28,29]. The inhibitors were dissolved in water or DMSO at a concen-
tration of 20–50 mM. Freshly prepared inhibitor stock solution was
then introduced into crystallization droplets to a final inhibitor concen-
tration of ~0.2 mM for p38, and up to 1.0 mM for ERK2, and soaked for
4–6 hours. The crystals were flash-frozen in liquid propane and main-
tained at –175°C during the data collection. X-ray diffraction data were
collected on an Raxis IIC image plate with a rotating-anode generator
(Rigaku, Tokyo; Model RU-300) using 1.54 Å radiation at The Univer-
sity of Texas Southwestern Medical Center at Dallas. The data were
integrated and scaled in the program HKL [52]. The crystals soaked
with inhibitors had the same space group and cell constants as those
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of native protein crystals. The sigmaA-weighted [53] |Fo|–|Fc| difference
electron-density maps were calculated by the program REFMAC in the
CCP4 suite [54] using phases derived from native p38 or ERK2 coor-
dinates. The inhibitor molecules were built in the program Insight II and
fit to electron density using the program O [55]. The initial protein–
inhibitor complex models were subjected to simulated annealing
(T = 1000K) in the program X-PLOR [56]. Subsequent cycles of refine-
ment were performed using REFMAC, followed by positional and
B-factor refinements in X-PLOR, and model building in O. Bulk solvent
correction was applied at the final stage of refinement in X-PLOR. The
backbone conformation of at least 86% of the residues is within the
most favored regions of the Ramachandran plot, with none in disal-
lowed regions, as defined using the program PROCHECK [57].
The p38 kinase activity was measured using the epidermal growth
factor receptor (EGFR) derived peptide, T669, as substrate. Reac-
tions were carried out in 96-well plates (from Corning) in a 30 µl
volume. The reactions contained (in final concentration) 25 mM Hepes
(pH7.5), 8 mM MgCl2, 0.17 mM ATP (the Km[ATP] of p38 [25]),
2.5 µCi of [γ-32P]ATP, 0.2 mM sodium orthovanadate, 1 mM DTT,
0.1% BSA, 10% glycerol, 0.67 mM T669 peptide and 2–4 nM of
yeast-expressed, activated and purified p38. Reactions were initiated
by the addition of [γ-32P]Mg/ATP, and incubated for 25 min at 37°C.
Inhibitors (dissolved in DMSO) were incubated with the reaction
mixture on ice for 30 min prior to adding the 32P-ATP. The final DMSO
concentration was 0.16%. Reactions were terminated by adding 10 µl
of 0.3 M phosphoric acid, and phosphorylated peptide was isolated
from the reactions by capturing it on p81 phosphocellulose filters.
Filters were washed with 75 mM phosphoric acid, and incorporated
32P was quantified using a β-scintillation counter. Under these condi-
tions, the specific activity of p38 was 400–450 pmol/pmol enzyme,
and the activity was linear for up to 2 hrs of incubation. The kinase-
activity values were obtained after subtracting values generated in the
absence of substrate, which were 10–15% of total values.
Accession numbers
Coordinates have been deposited in the Brookhaven Protein Data Bank.
The access codes for complexes of p38 with SB1, SB2, SB3, and SB4
are 1a9u, 1b16, 1bmk, and 1b17 respectively; the codes for complexes
of ERK2 with olomoucine and SB4 are 3erk and 4erk respectively.
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